Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Dyne Therapeutics

Tracked across 3 events · 18 articles · First seen Jun 03, 2026 · Last active Jul 28, 2026

Sentiment
47
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of its ACHIEVE trial for zeleciment basivarsen, a significant step towards potential market approval and commercialization of a treatment for Myotonic Dystrophy Type 1 (DM1). This milestone could positively impact the company's stock price and future revenue streams.
Jun 03, 2026 · 6 articles
2 30
Business
Impact: Dyne raised $431.4 million through the offering, strengthening its balance sheet to fund clinical programs.
Jul 21, 2026 · 6 articles
2 40
Regulatory
Impact: Dyne Therapeutics received FDA clearance for its IND application for DYNE-302, allowing it to initiate a Phase 1 trial for FSHD. This expands its clinical pipeline and validates its FORCE platform.
Jul 28, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Dyne Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.